Iovance Biotherapeutics (IOVA) is back in focus after first quarter 2026 results showed revenue of US$71.43 million, a reduced net loss, and management commentary centered on Amtagvi adoption and long term growth plans.

The stock has pulled back recently, with a 1-day share price return of 3.78% down and a 7-day share price return of 10.55% down. However, the 90-day share price return of 36.92% and 1-year total shareholder return of 98.88% suggest momentum has been rebuilding after much weaker multi year total shareholder returns.

If you are looking beyond a single biotech story, this could be a good moment to see what else is moving and check out 33 healthcare AI stocks

So with Iovance delivering higher revenue, a smaller net loss and trading well below some analyst price targets, should you see the recent pullback as a chance to buy into future growth, or assume the market has it fully priced in?

Most Popular Narrative: 57.4% Undervalued

The most followed narrative pegs Iovance Biotherapeutics' fair value at $8.35 per share versus the last close at $3.56, framing a large valuation gap that rests heavily on growth and margin assumptions.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Curious what has to happen for that kind of upside to make sense? Revenue growth, margin expansion and a future earnings multiple all have to line up just right.

Result: Fair Value of $8.35 (UNDERVALUED)

However, the story can break if regulatory setbacks linger or if heavy reliance on Amtagvi and its complex, costly manufacturing model continues to pressure margins and cash needs.

Another View: Market Ratio Check

That fair value of $8.35 comes from a discounted cash flow style approach, but the market is also sending mixed signals through simple sales multiples. Iovance trades on a P/S of 5.6x, which sits just above its own fair ratio of 5.2x and well below the peer average of 29.9x and the broader US Biotechs industry at 9.7x. In plain terms, the stock looks slightly expensive versus its own fundamentals, yet cheap compared with peers, raising a question for you as an investor: which yardstick matters more for your thesis?

Next Steps

With sentiment this mixed, do not just take these narratives at face value. Move quickly, review the underlying numbers yourself, and weigh up the stock’s 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If this story has sharpened your thinking, do not stop here. Use the screener to spot other stocks that fit the kind of portfolio you want.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 44 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by checking out the 69 resilient stocks with low risk scores focused on stocks with lower risk scores.
• Add potential income pillars to your watchlist by reviewing companies in the 13 dividend fortresses offering higher dividend yields.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.